Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $32.16 on Friday. The stock’s 50-day moving average is $36.13 and its 200 day moving average is $35.15. Supernus Pharmaceuticals has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market cap of $1.79 billion, a P/E ratio of 30.06 and a beta of 0.83.

Insider Transactions at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 over the last 90 days. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in SUPN. Principal Financial Group Inc. increased its position in shares of Supernus Pharmaceuticals by 5.4% in the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock valued at $8,899,000 after purchasing an additional 14,566 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at $1,774,000. Los Angeles Capital Management LLC purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter worth about $625,000. Victory Capital Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after acquiring an additional 7,833 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Supernus Pharmaceuticals by 14.9% in the 3rd quarter. Natixis Advisors LLC now owns 39,318 shares of the specialty pharmaceutical company’s stock valued at $1,226,000 after acquiring an additional 5,113 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.